EGFRvIII is associated with EGFR amplification in 30–40% of glioblastoma cases [19], and the expression of EGFRvIII is a negative prognostic marker for the overall survival in patients with glioblastoma surviving at least 1 year long [20,21]. This evidence concerns the gene EGFR and glioblastoma.